603077 和邦生物
2026/03 - 三个月
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额22,6141,076,237467,93180,3322,644,263
投资活动产生之现金流量净额(243,061)(1,348,564)(1,387,119)(782,227)(807,242)
筹资活动产生之现金流量净额369,262143,4234,847,210(943,597)1,004,984
汇率变动对现金及现金等价物的影响(24,821)(38,462)18,7095,46521,856
现金及现金等价物净增加/(减少)123,994(167,366)3,946,731(1,640,026)2,863,860
期初现金及现金等价物余额6,681,6736,851,5632,904,8324,544,8581,680,998
期末现金及现金等价物余额6,805,6686,684,1976,851,5632,904,8324,544,858